Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.68M | $6.15M | $4.23M | $6.48M | $6.76M | $29.8M | $31.2M | $18.7M | $7.83M |
| Revenue growth | — | — | 265.5% | -31.3% | 53.3% | 4.3% | 340.1% | 5.0% | -40.1% | -58.2% |
| Gross profit | — | $476K | $3.24M | — | — | — | — | — | — | — |
| Gross margin | — | 28.3% | 52.7% | — | — | — | — | — | — | — |
| Operating income | -$48.6M | -$54.4M | -$84.8M | -$111M | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$142M | -$76.4M |
| Operating margin | — | -3230.0% | -1378.3% | -2627.3% | -785.4% | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Net income | -$48.1M | -$68.5M | -$133M | -$161M | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132M | -$64.9M |
| Net margin | — | -4071.5% | -2158.0% | -3817.2% | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
| EPS (diluted) | -$2.25 | -$2.44 | -$4.03 | -$3.90 | -$1.20 | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.6M | -$54.7M | -$101M | -$96.4M | -$38.6M | -$52.1M | -$67.6M | -$78.3M | -$20.1M | -$47.1M |
| Capital expenditures | $232K | $1.24M | $1.36M | $1.61M | $453K | $308K | $605K | $1.31M | $121K | $111K |
| Free cash flow | -$34.8M | -$55.9M | -$102M | -$98.1M | -$39.1M | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30.2M | $20.2M | $57.0M | $34.2M | $22.1M | $27.3M | $45.3M | $39.9M | $24.6M | $20.0M |
| Total assets | $176M | $244M | $276M | $98.3M | $70.8M | $251M | $255M | $197M | $220M | $160M |
| Total liabilities | $6.59M | $18.2M | $60.4M | $28.4M | $33.1M | $53.9M | $57.0M | $40.2M | $64.8M | $57.4M |
| Long-term debt | — | — | $29.9M | — | $10.7M | — | — | — | — | — |
| Shareholders' equity | $169M | $225M | $215M | $69.9M | $37.6M | $197M | $198M | $157M | $156M | $103M |
| Retained earnings | -$90.9M | -$159M | -$292M | -$454M | -$505M | -$595M | -$682M | -$771M | -$903M | -$968M |
| Shares (wtd avg diluted) | 26.1M | 30.9M | 41.2M | 41.3M | 42.5M | 56.7M | 65.2M | 69.8M | 77.3M | 123M |
Every figure is extracted from Aclaris Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.